VALO THERAPEUTICS
Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenoviruses into targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.
VALO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Oncology Therapeutics
Founded:
2016-01-01
Address:
Helsinki, Southern Finland, Finland
Country:
Finland
Website Url:
http://www.valotx.com
Total Employee:
11+
Status:
Active
Contact:
+44 20 3920 7649
Email Addresses:
[email protected]
Total Funding:
11.6 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager Google Analytics LetsEncrypt SSL By Default Global Site Tag Google Universal Analytics
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Merus
Merus is a biomedical company engaged in the discovery and development of antibody-based biopharmaceuticals.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Investors List
European Innovation Council
European Innovation Council investment in Grant - Valo Therapeutics
Business Finland
Business Finland investment in Debt Financing - Valo Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-16 | Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer |
Official Site Inspections
http://www.valotx.com Semrush global rank: 7.37 M Semrush visits lastest month: 800
- Host name: buzz.d-webhost.orphans.co.uk
- IP address: 138.201.193.103
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Valo Therapeutics"
Reinventing Cancer Immunotherapy | Valo Therapeutics LTD
ValoTx is developing novel immunotherapies for cancer that are projected to transform treatment and prevention for millions of patients. Our unique approach, based on the selective use of …See details»
About | Valo Therapeutics LTD
ValoTx is positioned to transform the field of immunotherapy in cancer. ValoTx’s technology uniquely combines the best qualities of several distinct clinically proven immunotherapy concepts – oncolytic virus therapy, peptide vaccination …See details»
Valo Therapeutics selects Exothera to develop large …
Helsinki, Finland, January 11th, 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service …See details»
Valo Therapeutics - Crunchbase Company Profile
Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), …See details»
Valo Therapeutics selects Exothera to develop large …
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced...See details»
Valo Therapeutics Announces Two European Patents Granted for …
HELSINKI, Finland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, …See details»
Reinventing immunotherapy - NLS - Nordic Life Science
Oct 26, 2022 · Immunotherapy company Valo Therapeutics could play an important part in modern cancer care, using a highly adaptable platform effective for a wide range of cancers. Valo Therapeutics (ValoTx), founded in 2016, is a …See details»
ValoTx Approach and Technologies | Valo Therapeutics …
PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) is an innovative and unique way of combining two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine, …See details»
Valo Therapeutics Announces Regulatory Approval to Expand …
HELSINKI, Finland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received …See details»
Valo Therapeutics selects Exothera to develop large …
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced...See details»
Valo Therapeutics Announces Regulatory Approval to Expand
Nov 29, 2023 · Valo Therapeutics Oy (Helsinki) is an immunotherapy company developing antigen-coated oncolytic viruses as therapeutic vaccines against cancer. The ValoTx lead …See details»
Valo Therapeutics Announces First Patient Dosed with
HELSINKI, Finland, May 23, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces that the first patient …See details»
News and Press Releases | Valo Therapeutics LTD
Helsinki, Finland & Evry, France, 13 June 2023 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract …See details»
Valo Therapeutics Secures EUR 2.23 million from the European …
HELSINKI, Finland, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, …See details»
Valo Therapeutics selects Exothera to develop large-scale oncolytic ...
Jan 11, 2023 · Valo Therapeutics Oy announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization specialized in gene therapy, vaccines, …See details»
Valo Therapeutics and Texcell Announce Research - GlobeNewswire
Jun 13, 2023 · HELSINKI, Finland and EVRY, France, June 13, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for …See details»
Valo Therapeutics Announces New Funding for Immuno-Oncology …
Feb 7, 2020 · Valo Therapeutics Limited (Valo Tx), an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, today announced it had …See details»
Valo Therapeutics Announces Regulatory Approval to Expand …
Helsinki, Finland, 29 Nov 2023 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany’s …See details»
Valo Therapeutics - Craft
Valo Therapeutics (ValoTx) is a biotechnology company that develops novel immunotherapies for cancer, oncology, and infectious diseases. It offers Peptide-coated Conditionally Replicating …See details»
Valo Therapeutics Announces Two European Patents Granted
HELSINKI, Finland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, …See details»